MDV Pharma
ActiveSummary
MDV Pharma has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €475,152 and a net result of €258,448. Equity is growing by about 61% per year across the filed financial years. Its solvency ranks better than 40% of 12,404 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Highest result from 2020 to 2025net €258,448 ▲174%
Net result €258,448, the highest in the series.
14-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
17-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Back to profitnet €171,489
Net result €171,489 after one loss-making year.
31-12
Financial
Equity above €200,000equity €240,274 ▲177%
Equity rises from €86,785 to €240,274.
25-04
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Weakest financial yearnet -€45
Net result drops to -€45, the lowest in the series; recovery starts the following year.
23-06
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.